Armata Pharmaceuticals, Inc. (FRA:TG1N)

Market Cap	220.66M
Revenue (ttm)	4.31M
Net Income (ttm)	-39.97M
Shares Out	n/a
EPS (ttm)	-1.89
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	71
Open	6.65
Previous Close	6.25
Day's Range	6.65 - 6.65
52-Week Range	0.70 - 6.65
Beta	n/a
RSI	65.11
Earnings Date	Mar 16, 2026

About Armata Pharmaceuticals

Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company’s product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has research collaboration agreement with Merck Sharp & Dohme Corp. for developing syn...

• Industry: Biological Products, Except Diagnostic Substances
• CEO: Deborah Birx
• Employees: 60
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: TG1N

Financial Performance

In 2024, Armata Pharmaceuticals's revenue was $5.17 million, an increase of 14.24% compared to the previous year's $4.53 million. Losses were -$18.92 million, -72.60% less than in 2023.

Financial numbers in USD